CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 136 enrolled
Drug / intervention
Liraglutide +1 moredrug
Likely dose
Liraglutide 0.6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03523273
NCT03523273Phase 2Completed
CompareCT.gov

Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity

Michael Camilleri, MD·interventional·Posted May 14, 2018·Updated Jun 23, 2022

In Brief

A Phase 2 clinical trial evaluating Liraglutide and Placebo for Obesity. Completed, enrolled 136 participants across 1 site.

Detailed Summary

This study is being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 14, 2018
Enrollment StartNov 29, 2017
Primary CompletionAug 31, 2021
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 8.1 years ago

Interventions

Liraglutidedrug

Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.

Placebodrug

Placebo administration will match the study drug.